Clinical Scorecard: New Possibilities for Minimally Invasive Bleb Surgery
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Minimally invasive bleb surgery (MIBS) achieves intraocular pressure (IOP) reduction by creating subconjunctival filtration pathways with improved safety and recovery compared to traditional filtering surgeries. |
| Target Population | Patients with glaucoma, especially those at high risk of vision loss requiring stronger IOP lowering but who may not tolerate traditional filtering surgery. |
| Care Setting | Operating room and potentially clinic-based settings as new devices and techniques develop. |
Key Highlights
- MIBS aims to bridge the gap between the efficacy of traditional filtering surgeries and the safety profile of angle-based MIGS.
- Current US-available MIBS device is the Xen 45 gel stent; other devices like PreserFlo MicroShunt and Calibreye titratable shunt are in trials or international use.
- Emerging nonimplant and office-based MIBS approaches are under development to expand treatment options beyond the operating room.
Guideline-Based Recommendations
Diagnosis
- Identify patients with glaucoma requiring significant IOP reduction who may benefit from MIBS as an alternative to traditional filtering surgery or angle-based MIGS.
Management
- Consider MIBS for patients needing IOP lowering approaching that of trabeculectomy but with improved safety and faster recovery.
- Use antifibrotic agents to optimize long-term success by modulating subconjunctival healing.
Monitoring & Follow-up
- Monitor postoperative IOP and bleb function closely due to dependence on subconjunctival healing.
- Assess for potential complications related to device implantation or filtration failure.
Risks
- Potential for subconjunctival fibrosis affecting long-term success.
- Risks associated with device implantation and postoperative care, though generally lower than traditional filtering surgeries.
Patient & Prescribing Data
Glaucoma patients requiring enhanced IOP reduction with a favorable safety profile.
MIBS devices like Xen 45 provide sustained IOP reduction but may not match trabeculectomy efficacy; newer devices under investigation may improve outcomes and broaden applicability.
Clinical Best Practices
- Select MIBS candidates carefully based on disease severity and risk profile.
- Employ antifibrotic agents to improve surgical success rates.
- Stay informed on emerging devices and clinical trial data to optimize patient care.
- Consider office-based MIBS approaches as they become available to enhance patient convenience.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.